Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $18.7752W HIGH $30.42
Volume
2.35 M
Value Traded
86.30 M
Short % Float
6.51%
-1.14%Week
-12.5%1 Month
-14.72%3 Month
-9.1%6 Month
-47.16%5 Year
-8.65%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.77 B
EPS (TTM)
0.59
P/E Ratio
39.66
Ent. Value
4.08 B
Total Shares
160.62 M
Float Shares
156.87 M
Insiders
2.33%
Institutions
117.88%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NVST Catalyst Timeline
Dated clinical, regulatory and corporate events for Envista Holdings Corporation
Past FDA Catalysts and PDUFA Decisions
How NVST actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D23 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Top 88%
Small Cap(rank 579 of 658)
Percentile Rank
Envista Holdings Corporation faces pipeline headwinds (23/100), with 1 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every NVST program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Reis MischaOfficer (SVP, Strategy & Bus. Dev.) | Sell | -8,000 27,321 held | $27.50 | 08/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NVST
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 0.6 % (50 %) | 15.81 M | 600.00 K | 71.43% ( 250.00 K) |
NVST Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NVST ranks across every disease it competes in
Competitive Position is a premium feature
See how NVST ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNVST News
NVSTEnvista Announces Participation in Baird 2026 Global Healthcare Conference
Envista Holdings Corporation announced its participation in the Baird 2026 Global Healthcare Conference, scheduled for September 15, 2026. The event will feature a fireside chat from 9:40 to 10:10 AM ET. A live audio webcast will be available for investors, highlighting Envista's leadership in the dental industry.
Read more →NVSTEnvista Reports First Quarter 2026 Results
Envista Holdings Corporation reported strong first quarter results for 2026, achieving a 9.5% core revenue growth and a 50% increase in adjusted EPS compared to the previous year. The company also announced a $300 million share repurchase program, reflecting confidence in its financial performance. However, it faced challenges with negative operating and free cash flows during the quarter.
Read more →NVST▲ +5.4%on this news
Envista Schedules First Quarter 2026 Earnings Call
Envista Holdings Corporation will announce its financial results for the first quarter of 2026 on May 6, 2026. The company will host a conference call at 2:00 PM PT to discuss these results, which will be accessible via a webcast. A replay of the call will be available for one year, and relevant materials will be posted on their website.
Read more →About Envista Holdings Corporation
Headquarters200 S. KRAEMER BLVD., BLDG. E, BREA, CA, 92821
BIOPHARMAWATCH ELITE PLUS
Trade the next NVST catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime